

## Section 708A(5)(e) Notice – Issue of Cynata Therapeutics Limited shares without a prospectus

**Melbourne, Australia; 24 April 2023:** Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”) has today issued 9,302,325 fully paid ordinary shares in the Company, which completes the unconditional component of the share placement which was announced to ASX on 6 April 2023 (**Placement**).

A total of 640,694 shares remain to be issued to Directors pursuant to the Director Placement (subject to shareholder approval), which is expected to occur on 31 May 2023.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

1. the Company issued 9,302,325 ordinary shares in the Company without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) sections 674 and 674A of the Act; and
3. as at the date of this notice, there is no information that is ‘excluded information’ (within the meaning of section 708A(7) and section 708A(8) of the Act).

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [littlebigdealconsulting@gmail.com](mailto:littlebigdealconsulting@gmail.com)

### About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**